19F-lanthanide complexes with increased sensitivity for 19F-MRI: Optimization of the MR acquisition

Magnetic Resonance in Medicine

Volumn 66, Issue 4, 2011, Pages 931-936

  Chalmers, Kirsten H ^a   Kenwright, Alan M ^a   Parker, David ^a   Blamire, Andrew M ^b  

^a DURHAM UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

fluorine; lanthanide; magnetic resonance imaging; relaxation

Indexed keywords

FLUORINE; MAGNETIC RESONANCE IMAGING; RARE EARTH ELEMENTS;

BACKGROUND SIGNALS; LANTHANIDE COMPLEX; LONGITUDINAL RELAXATION; MILLIMOLAR CONCENTRATIONS; NATURALLY OCCURRING; PHANTOM EXPERIMENT; RELAXATION; TRANSVERSE RELAXATION RATE;

MOLECULAR IMAGING;

DYSPROSIUM; ERBIUM; FLUORINE; HOLMIUM; LANTHANIDE; TERBIUM; THULIUM; YTTRIUM;

ARTICLE; CHEMICAL STRUCTURE; COMPLEX FORMATION; FLUORINATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; MAGNETISM; MOLECULAR IMAGING; MOLECULE; RADIOACTIVITY; CHEMISTRY; IMAGE ENHANCEMENT; IMAGE QUALITY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY;

FLUORINE; IMAGE ENHANCEMENT; LANTHANOID SERIES ELEMENTS; MAGNETIC RESONANCE IMAGING; PHANTOMS, IMAGING; SENSITIVITY AND SPECIFICITY;

EID: 80052966202     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22881     Document Type: Article

References (20)

1. Morse DL, Gillies RJ,. Molecular imaging and targeted therapies. Biochem Pharmacol 2010; 80: 731-738.
2. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS,. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7: 591-607. (Pubitemid 351927724)
3. Massoud TF, Gambhir SS,. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-580. (Pubitemid 36307540)
4. Wolf W, Presant CA, Waluch V,. F-19-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 2000; 41: 55-74.
5. Glaholm J, Leach MO, Collins D, Aljehazi B, Sharp JC, Smith TAD, Adach J, Hind A, McCready VR, White H,. Comparison of 5-Fluorouracil pharmacokinetics following intraperitoneal and intraveneous administration using in vivo F-19 magnetic resonance spectroscopy. Br J Radiol 1990; 63: 547-553. (Pubitemid 20218900)
6. Kamm YJL, Heerschap A, van den Bergh EJ, Wagener DJT,. F-19-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. Anticancer Drugs 2004; 15: 229-233. (Pubitemid 38429414)
7. Klomp DWJ, van Laarhoven HWM, Kentgens APM, Heerschap A,. Optimization of localized F-19 magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. Magn Reson Med 2003; 50: 303-308. (Pubitemid 36950849)
8. Komoroski RA, Newton JEO, Cardwell D, Sprigg J, Pearce J, Karson CN,. In-vivo F-19 spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Reson Med 1994; 31: 204-211. (Pubitemid 24044091)
9. Bolo NR, Hode Y, Macher JP,. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo. MAGMA 2004; 16: 268-276. (Pubitemid 39006330)
10. Reid DG, Murphy PS,. Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism. Drug Discov Today 2008; 13: 473-480.
11. Ogawa M, Nitahara S, Aoki H, Ito S, Narazaki M, Matsuda T,. Fluorinated polymer nanoparticles as a novel F-19 MRI contrast agent prepared by dendrimer-initiated living radical polymerization. Macromol Chem Phys 2010; 211: 1369-1376.
12. Ogawa M, Nitahara S, Aoki H, Ito S, Narazaki M, Matsuda T,. Synthesis and evaluation of water-soluble fluorinated dendritic block-copolymer nanoparticles as a F-19-MRI contrast agent. Macromol Chem Phys 2010; 211: 1602-1609.
13. Criscione JM, Le BL, Stern E, Brennan M, Rahner C, Papademetris X, Fahmy TM,. Self-assembly of pH-responsive fluorinated dendrimer-based particulates for drug delivery and noninvasive imaging. Biomaterials 2009; 30: 3946-3955.
14. Neubauer AM, Myerson J, Caruthers SD, Hockett FD, Winter PM, Chen JJ, Gaffney PJ, Robertson JD, Lanza GM, Wickline SA,. Gadolinium-modulated F-19 signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med 2008; 60: 1066-1072.
15. Kenwright AM, Kuprov I, De Luca E, Parker D, Pandya SU, Senanayake PK, Smith DG,. F-19 NMR based pH probes: lanthanide(III) complexes with pH-sensitive chemical shifts. Chem Commun 2008; 2514-2516. (Pubitemid 351752927)
16. Senanayake PK, Kenwright AM, Parker D, van der Hoorn SK,. Responsive fluorinated lanthanide probes for F-19 magnetic resonance spectroscopy. Chem Commun 2007; 2923-2925. (Pubitemid 47052145)
17. Chalmers KH, De Luca E, Hogg NHM, Kenwright AM, Kuprov I, Parker D, Botta M, Wilson JI, Blamire AM,. Design principles and theory of paramagnetic fluorine-labelled lanthanide complexes as probes for F-19 magnetic resonance: a proof-of-concept study. Chem-Eur J 2010; 16: 134-148.
18. Chalmers KH, Botta M, Parker D,. Strategies to enhance signal intensity with paramagnetic fluorine-labelled lanthanide complexes as probes for 19F magnetic resonance. Dalton Trans 2011; 40: 904-913.
19. Ernst RR, Bodenhausen G, Wokaun A,. Principles of nuclear magnetic resonance in one and two dimensions. Oxford: Oxford University Press; 1987.
20. Huang ZH, Sengar RS, Nigam A, Abadjian MC, Potter DM, Grotjahn DB, Wiener EC,. A fluorinated dendrimer-based nanotechnology platform new contrast agents for high field imaging. Investig Radiol 2010; 45: 641-654.